Sweden
· Delayed Price · Currency is SEK Sprint Bioscience AB Statistics
Total Valuation
Sprint Bioscience AB has a market cap or net worth of SEK 86.58 million. The enterprise value is 50.57 million.
| Market Cap | 86.58M |
| Enterprise Value | 50.57M |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Sprint Bioscience AB has 69.82 million shares outstanding. The number of shares has increased by 22.41% in one year.
| Shares Outstanding | 69.82M |
| Shares Change (YoY) | +22.41% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 51.99% |
| Owned by Institutions (%) | 27.81% |
| Float | 23.61M |
Valuation Ratios
The trailing PE ratio is 5.88.
| PE Ratio | 5.88 |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| PB Ratio | 4.63 |
| P/FCF Ratio | 4.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.36, with an EV/FCF ratio of 2.44.
| EV / Earnings | 3.44 |
| EV / Sales | 0.59 |
| EV / EBITDA | 3.36 |
| EV / EBIT | 3.54 |
| EV / FCF | 2.44 |
Financial Position
The company has a current ratio of 1.47
| Current Ratio | 1.47 |
| Quick Ratio | 1.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 128.60% and return on invested capital (ROIC) is 78.04%.
| Return on Equity (ROE) | 128.60% |
| Return on Assets (ROA) | 25.05% |
| Return on Capital (ROIC) | 78.04% |
| Revenue Per Employee | 2.39M |
| Profits Per Employee | 408,833 |
| Employee Count | 28 |
| Asset Turnover | 2.42 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.09% in the last 52 weeks. The beta is 0.50, so Sprint Bioscience AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -46.09% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 39.94 |
| Average Volume (20 Days) | 80,879 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sprint Bioscience AB had revenue of SEK 86.21 million and earned 14.72 million in profits. Earnings per share was 0.21.
| Revenue | 86.21M |
| Gross Profit | 66.24M |
| Operating Income | 14.29M |
| Pretax Income | 14.72M |
| Net Income | 14.72M |
| EBITDA | 15.06M |
| EBIT | 14.29M |
| Earnings Per Share (EPS) | 0.21 |
Balance Sheet
| Cash & Cash Equivalents | 36.01M |
| Total Debt | n/a |
| Net Cash | 36.01M |
| Net Cash Per Share | 0.52 |
| Equity (Book Value) | 18.69M |
| Book Value Per Share | 0.27 |
| Working Capital | 14.04M |
Cash Flow
In the last 12 months, operating cash flow was 23.94 million and capital expenditures -3.21 million, giving a free cash flow of 20.73 million.
| Operating Cash Flow | 23.94M |
| Capital Expenditures | -3.21M |
| Free Cash Flow | 20.73M |
| FCF Per Share | 0.30 |
Margins
Gross margin is 76.84%, with operating and profit margins of 16.58% and 17.07%.
| Gross Margin | 76.84% |
| Operating Margin | 16.58% |
| Pretax Margin | 17.07% |
| Profit Margin | 17.07% |
| EBITDA Margin | 17.46% |
| EBIT Margin | 16.58% |
| FCF Margin | 24.04% |
Dividends & Yields
Sprint Bioscience AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.41% |
| Shareholder Yield | -22.41% |
| Earnings Yield | 17.00% |
| FCF Yield | 23.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |